MedTrace Logo

New York City Observational Study of Mpox Immunity

NCT05654883 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 174

Last updated 2025-10-30

No results posted yet for this study

Summary

The goal of this study is to assess the immune response, tolerance, and safety of the low-dose intradermal (forearm) mpox vaccine in people who are HIV+ compared to people who are HIV-, and compared to the standard-dose subcutaneous (upper arm) vaccine. The resulting data will fill knowledge gaps, inform public health practices, and address community concerns about the absence of data for low-dose intradermal mpox vaccinations in people living with HIV.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Angelica Kottkamp, MD · NYU Langone Health

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-11
Primary Completion
2023-09-11
Completion
2026-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05654883 on ClinicalTrials.gov